Prostate cancer screening is controversial — the screening decision must be based on high-quality evidence
Screening for cancer, especially screening for prostate cancer with prostate-specific antigen (PSA), is one of the most controversial subjects in medicine today. The main dilemma is that one aims for a beneficial effect on the population level, but on the individual level, some will only be harmed without any gain from participation — such as those in whom the cancer detected is already too advanced at diagnosis, and those diagnosed with a harmless disease that will not surface as a clinical cancer during the lifetime (overdiagnosis). These individuals will unnecessarily be “labelled” as patients for many years, are likely to be treated unnecessarily and suffer from the side effects of treatment (overtreatment) without altering the risk of prostate cancer mortality.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Roobol MJ, Carlsson SV. Risk stratification in prostate cancer screening. Nat Rev Urol 2013; 10: 38-48.
- 2. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010; 11: 725-732.
- 3. Heijnsdijk EA, Wever EM, Auvinen A, et al. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med 2012; 367: 595-605.
- 4. Evans SM, Millar JL, Davis ID, et al. Petterns of care for men diagnosed with prostate cancer from 2008 to 2011. Med J Aust 2013; 198: 543-548.
- 5. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010; 28: 1117-1123.
- 6. Del Mar CB, Glasziou PP, Hirst GH, et al. Should we screen for prostate cancer? A re-examination of the evidence. Med J Aust 2013; 198: 525-527.
- 7. Labrie F, Candas B, Cusan L, et al. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate 2004; 59: 311-318.
- 8. Kjellman A, Akre O, Norming U, et al. 15-year followup of a population based prostate cancer screening study. J Urol 2009; 181: 1615-1621.
- 9. Sandblom G, Varenhorst E, Rosell J, et al. Randomised prostate cancer screening trial: 20 year follow-up. BMJ 2011; 342: d1539.
- 10. Andriole GL, Crawford ED, Grubb RL 3rd, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012; 104: 125-132.
- 11. Schröder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012; 366: 981-990.
- 12. Roobol MJ, Carlsson S, Hugosson J. Meta-analysis finds screening for prostate cancer with PSA does not reduce prostate cancer-related or all-cause mortality but results likely due to heterogeneity - the two highest quality studies identified do find prostate cancer-related mortality reductions. Evid Based Med 2011; 16: 20-21.
- 13. Carlsson S, Vickers AJ, Roobol M, et al. Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review. J Clin Oncol 2012; 30: 2581-2584.
- 14. Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev 2013; (1): CD004720.
- 15. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003; 95: 868-878.
- 16. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from US prostate cancer incidence trends J Natl Cancer Inst 2002; 94: 981-990.
- 17. Sakr WA, Grignon DJ, Crissman JD, et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994; 8: 439-443.
- 18. Schwartz KL, Grignon DJ, Sakr WA, Wood DP Jr. Prostate cancer histologic trends in the metropolitan Detroit area, 1982 to 1996. Urology 1999; 53: 769-774.
- 19. Humphrey PA, Keetch DW, Smith DS, et al. Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. J Urol 1996; 155: 816-820.
- 20. Popiolek M, Rider JR, Andrén O, et al. Natural history of early, localized prostate cancer: a final report from three decades of follow-up. Eur Urol 2013; 63: 428-435.
- 21. Martin AJ, Lord SJ, Verry HE, et al. Risk assessment to guide prostate cancer screening decisions: a cost-effectiveness analysis. Med J Aust 2013; 198: 549-553.
- 22. Stricker PD, Frydenberg M, Kneebone A, Chopra S. Informed prostate cancer risk-adjusted testing: a new paradigm. BJU Int 2012; 110 Suppl 4: 30-34.
- 23. Smith DP, King MT, Egger S, et al. Quality of life three years after diagnosis of localised prostate cancer: population based cohort study. BMJ 2009; 339: b4817.
No relevant disclosures.